EP2217292A1 - Chirurgische prothese zur plastischen rekonstruktion - Google Patents
Chirurgische prothese zur plastischen rekonstruktionInfo
- Publication number
- EP2217292A1 EP2217292A1 EP08845613A EP08845613A EP2217292A1 EP 2217292 A1 EP2217292 A1 EP 2217292A1 EP 08845613 A EP08845613 A EP 08845613A EP 08845613 A EP08845613 A EP 08845613A EP 2217292 A1 EP2217292 A1 EP 2217292A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- prosthesis
- hydrophilic
- elastomer
- silicone
- implant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920003023 plastic Polymers 0.000 title claims abstract description 6
- 241000894006 Bacteria Species 0.000 claims abstract description 25
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 17
- 229920001296 polysiloxane Polymers 0.000 claims description 37
- 229920001971 elastomer Polymers 0.000 claims description 14
- 239000000806 elastomer Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000011859 microparticle Substances 0.000 claims description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 239000004332 silver Substances 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 230000003385 bacteriostatic effect Effects 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000956 alloy Substances 0.000 claims 1
- 229910045601 alloy Inorganic materials 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 229940100890 silver compound Drugs 0.000 claims 1
- 150000003379 silver compounds Chemical class 0.000 claims 1
- 239000007943 implant Substances 0.000 description 34
- 206010062575 Muscle contracture Diseases 0.000 description 8
- 208000006111 contracture Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000002775 capsule Substances 0.000 description 6
- 229920002379 silicone rubber Polymers 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 150000002433 hydrophilic molecules Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the present invention relates to a prosthesis intended to be implanted in a human body for plastic reconstitution, and more particularly to a soft tissue body prosthesis, and more specifically to a prosthesis or a breast implant.
- a well-known problem with breast implants is capsular contracture.
- Capsular contracture is the condition that occurs in approximately 5% of women, and in which the capsule surrounding the implant contracts in an attempt to isolate the implant from the rest of the body because a bacterial infection has occurred. developed. If this capsular contracture is not treated, it can lead to extrusion or permanent damage to the implant.
- Silicone elastomers have long been used in the manufacture of devices that can be implanted in the human body because they are chemically stable with the body as well as non-toxic.
- Staphylococcus epidermitis An example of such skin bacteria often isolated in association with capsular contracture is Staphylococcus epidermitis.
- This bacterium is an opportunistic bacterium that is not normally associated with an infection. It can, however, produce a bio film surrounding the bacteria that can be protective of the environment. The bacteria will preferably attach to a solid support and can then multiply. The bio film layer is the virulence factor that allows Staphylococcus epidermitis to survive where other bacteria are destroyed by the normal immune system. The bacteria can live for long periods of time with low metabolic rate.
- the bacterium Staphylococcus epidermitis can therefore attach to the silicone implant, especially during implantation, when a relatively large implant has passed through a small relative incision in the skin.
- the implant becomes colonized by the bacterium because of the high hydrophobicity of the external surface of the implant, (generally silicone for soft tissue prostheses) and the surface of the bacterium are both highly hydrophobic, and attract solids in a non-specific way. This allows the information of a bio film to slow growth on the external surface of the implant.
- these bacteria grow slowly, they can adhere to the external surface of the implant, remain dormant during periods of time equilibrium with the host, sometimes for several years, and then, for example, because of stress on the body, the bacteria stops living in balance with the body's immune system. At this time, under such imbalanced trigger conditions, the bacterium can rapidly replicate or at least exude exotoxins into its environment and cause inflammation on and around the capsule. Typical triggering conditions include loss or decrease in immune status due to diseases, drug treatments, etc., which will allow the bacteria to multiply.
- EP-0 057 033 and FR-2 822 383 describe methods for modifying the surfaces of breast implants. These methods are complex and therefore expensive to implement.
- the present invention aims to provide a prosthesis intended to be implanted in a human body for plastic reconstitution, which does not reproduce the aforementioned drawbacks.
- the present invention aims to provide a prosthesis, including a silicone breast prosthesis, for which the risks of capsular contracture are reduced.
- the present invention also aims to provide such a prosthesis which is simple and inexpensive to manufacture and to achieve, and which does not require modifications of the implantation process by the surgeon.
- the present invention therefore relates to a surgical prosthesis intended to be implanted in a human body, as described in claim 1.
- Fig. 1 is a cross-sectional view of a portion of a prosthesis, where the outer surface of the prosthesis is a silicone elastomer which is chemically modified to render it hydrophilic;
- Fig. 2 is a cross-sectional view of a portion of a prosthesis having a plurality of hydrophilic microparticles partially embedded in the outer surface of the prosthesis;
- Figure 3 is a cross-sectional view of a portion of a prosthesis having a hydrophilic layer coated on the outer surface of the prosthesis.
- the present invention consists in responding to the problem of post-implantation capsular contracture by attacking the hydrophobic / hydrophobic interaction between the surface of the prosthesis, which in the prior art is generally a hydrophobic surface, and potentially colonizing bacteria, also hydrophobic. If one disrupts the ability of the outer surface to become a substrate or a support for bacterial growth, then the bacterium will not be able to attach to this surface or produce a bio-protective film, with the adverse consequences induced described above. If the bacterium remains in a hydrophilic tissue and / or a hydrophilic fluid, then it will not be able to attach to the surface of the prosthesis, and the normal immune response of the host will "clean" the bacterium in a known manner.
- the invention therefore provides for making the prosthesis hydrophilic, made of elastomer, in particular silicone, to prevent any bacterial growth.
- the preferred embodiment of the invention which provides for chemically modifying the side and / or end groups of the silicone chain to make them more hydrophilic, will be described hereinafter in more detail.
- basic silicone building blocks (or chains) which are normally hydrophobic, are chemically modified to render the molecule hydrophilic. This can be achieved by substituting the methyl groups along the silicone backbone by any group hydrophilic. Examples of these hydrophilic groups could be (but not limited to) alcohols, ionic groups, organic molecules, etc., used alone or in combination with each other. The substitution could be carried out at the end of the molecule, over the entire length of the molecule, or a combination of these two variants. The concentration of the substitution can be modified to alter the importance of hydrophilicity.
- FIG. 1 is a cross-sectional view of a portion of a prosthesis 10 in which at least the outer surface 12 of the prosthesis is a silicone elastomer that is chemically modified to render the external surface hydrophilic.
- the silicone is modified from the outset to make it hydrophilic. After crosslinking, it is thus possible to form an implant that is hydrophilic from the start.
- modifying the surface of an already existing implant which is hydrophobic, as described in documents EP-0 057 033 and FR-2 822 383, requires the use of sophisticated and expensive means.
- the present invention makes it possible to obtain the desired hydrophilic properties in a simpler and less expensive manner.
- the entire prosthesis can be made from the outset from hydrophilic silicone (or other suitable elastomer).
- the invention may also provide for making a hydrophobic silicone prosthesis blank, and then dipping this blank one or more times in a hydrophilic modified silicone, to form one or more hydrophilic outer layers. After baking or crosslinking, the resulting prosthesis will have a hydrophobic internal support structure, and a hydrophilic external surface.
- there is no treatment of the external surface of an implant previously made of hydrophobic silicone but on the contrary, the external surface of the prosthesis is directly made of hydrophilic material during the manufacturing process of the prosthesis.
- Various variants that can be used in addition will be described below.
- These variants may include treatments of the surface of the implant, to further improve the hydrophilic properties of said surface. They may also include the use of a bactericidal and / or bacteriostatic material, in particular silver, especially in ionic form, which will have a non-toxic antimicrobial effect and which can therefore be used to kill or eliminate the bacterium if the one It must still develop on the surface of the prosthesis.
- This antimicrobial material may be embedded in or on the surface of the prosthesis and may, of course, be used in conjunction with hydrophilic surface properties of the prosthesis as mentioned above.
- silicone is the most widely used elastomer for implantable soft tissue prostheses. Consequently, the modification of the external surface of a silicone prosthesis will be described by way of non-limiting example.
- the external surface of a silicone implant according to the invention can be made even more hydrophilic by covalently attaching it to a hydrophilic end group, especially at the end of the manufacturing process, by putting the external surface in contact with a reagent, such as, for example, cyanogen bromide. These types of agents activate the molecule to covalently link it to other molecules, thus fixing molecules preferably over an area in which they were not previously existing.
- hydrophilic molecules can be covalently attached to the surface of the implant, making it even more hydrophilic.
- a hydrophobic end group may be covalently attached to the silicone surface, and subsequently separated, either chemically biologically, to render the surface hydrophilic.
- Still another method for rendering the outer surface of a silicone implant hydrophilic is to coat the silicone outer surface of the implant with silicone comprising monomers having both a hydrophobic end group and an end group opposite hydrophilic, to form the outermost layer. This "bipolar" silicone could be hydrophobically bonded to the silicone outer surface of the implant, leaving the opposing hydrophilic group exposed to the environment.
- the surface of the silicone implant may be coated with a hydrophobic-hydrophilic micelle.
- Fig. 2 is a cross-sectional view of a portion of a prosthesis 20 having a plurality of biocompatible hydrophilic particles 21 partially embedded in the outer surface 22.
- a prosthesis can be made by several manufacturing methods.
- a preferred method comprises the steps of forming a silicone shell by repeatedly dipping a prosthesis mandrel into a silicone dispersion, whereby the coating formed between the dives is fired. After the final layer of the silicone elastomer is formed on the outer surface and the shell is of desired thickness, a coating of solid microparticles of a biocompatible hydrophilic material is applied to the surface before the outermost layer is completely cooked.
- the biocompatible hydrophilic material may be hydrophilic throughout the entire microparticle or only on the surface of said microparticle.
- the silicone is completely cooked (for example by heating), so that an embedded portion of the microparticles is embedded in the fired outer layer of silicone and an exposed portion of the microparticles. extends outward from the silicone surface.
- the prosthesis thus formed can be implanted in the body of a person.
- hydrophilic biopolymers such as collagen and hyaluronic acid
- synthetic hydrophilic polymers such as polyvinylpyrrolidone
- FIG. 3 is a cross-sectional view of a portion of a prosthesis 30 having a hydrophilic layer or film 31 coated on the outer surface 32 of the implant.
- Such biocompatible hydrophilic film 31 may be attached to either a smooth surface or a textured surface of a silicone implant.
- Any solution, cream, compound, material, gel, that is reabsorbable in the body and that can interfere with the ability of a hydrophobic-hydrophobic interaction, can be used at the time of surgery to modify, break or interrupt the hydrophobic interaction -hydrophobe.
- This may for example include (but not limited to) lubricating materials for implant insertion, anti-adhesion materials, betadine, etc. These materials can be added directly to the implant pocket, on the surface of the implant itself, or a combination of both.
- Silver is well known to be a metal with therapeutic and low-toxicity capabilities. man. It can be bactericidal and / or bacteriostatic. Money or compounds containing money or silver nanoparticles, especially in ionic form, could be incorporated in the silicone or embedded in the surface of the prosthesis. Silver in any form can be used in conjunction with a previously mentioned hydrophilic external surface, or alone.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0758663A FR2922773A1 (fr) | 2007-10-29 | 2007-10-29 | Prothese chirurgicale |
PCT/EP2008/064604 WO2009056542A1 (fr) | 2007-10-29 | 2008-10-28 | Prothese chirurgicale pour la reconstitution plastique. |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2217292A1 true EP2217292A1 (de) | 2010-08-18 |
Family
ID=39402645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08845613A Withdrawn EP2217292A1 (de) | 2007-10-29 | 2008-10-28 | Chirurgische prothese zur plastischen rekonstruktion |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100234945A1 (de) |
EP (1) | EP2217292A1 (de) |
FR (1) | FR2922773A1 (de) |
WO (1) | WO2009056542A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202009007115U1 (de) * | 2009-05-18 | 2010-06-02 | Amoena Medizin-Orthopädie-Technik GmbH | Brustprothese |
WO2013112378A2 (en) * | 2012-01-24 | 2013-08-01 | Bvw Holding Ag | Implantable superhydrophobic surfaces |
CN104284685B (zh) | 2013-01-11 | 2017-06-27 | Bvw控股公司 | 生物选择性表面纹理 |
EP3484535B1 (de) | 2016-07-14 | 2022-01-19 | Hollister Incorporated | Hygienische medizinische vorrichtungen mit hydrophiler beschichtung und verfahren zur herstellung davon |
DK3391914T3 (da) * | 2017-04-21 | 2021-10-18 | Safe Implant Tech Aps | Guldpartikler til anvendelse i terapi til at forebygge eller mindske kapselkontraktur |
ES2923280B2 (es) * | 2022-03-15 | 2023-10-26 | American Erectil Device Srl | Implante de pene con cuerpos cavernosos sinteticos y barrera bactericida |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2498446B1 (fr) * | 1981-01-26 | 1985-05-24 | Inst Nat Sante Rech Med | Procede de traitement d'une prothese du type mammaire et prothese obtenue |
WO2000064506A1 (en) * | 1999-04-23 | 2000-11-02 | Agion Technologies, L.L.C. | Stent having antimicrobial agent |
FR2822383B1 (fr) * | 2001-03-23 | 2004-12-17 | Perouse Lab | Prothese pour reconstruction plastique a proprietes d'hydrophilicite ameliorees, et procede pour leur obtention |
US6913626B2 (en) * | 2001-08-14 | 2005-07-05 | Mcghan Jim J. | Medical implant having bioabsorbable textured surface |
-
2007
- 2007-10-29 FR FR0758663A patent/FR2922773A1/fr not_active Withdrawn
-
2008
- 2008-10-28 EP EP08845613A patent/EP2217292A1/de not_active Withdrawn
- 2008-10-28 US US12/740,076 patent/US20100234945A1/en not_active Abandoned
- 2008-10-28 WO PCT/EP2008/064604 patent/WO2009056542A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2009056542A1 * |
Also Published As
Publication number | Publication date |
---|---|
FR2922773A1 (fr) | 2009-05-01 |
WO2009056542A1 (fr) | 2009-05-07 |
US20100234945A1 (en) | 2010-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5064350B2 (ja) | 抗菌性高分子表面の生成方法 | |
Romanò et al. | Hyaluronic acid and its composites as a local antimicrobial/antiadhesive barrier | |
EP2217292A1 (de) | Chirurgische prothese zur plastischen rekonstruktion | |
DK2214737T3 (en) | Anti-microbial coatings for medical devices and methods of making and using the same | |
JP2665399B2 (ja) | 抗菌コートした医療用埋没物 | |
Shahid et al. | The prospects of antimicrobial coated medical implants | |
Neethirajan et al. | Medical biofilms—nanotechnology approaches | |
EP0641225B1 (de) | Verwendung von vernetztem kollagen zur herstellung einer nähfähigen bioverträglichen langsam resorbierbaren membran | |
Roosjen et al. | The use of positively charged or low surface free energy coatings versus polymer brushes in controlling biofilm formation | |
US11052177B2 (en) | Antimicrobial polymer layers | |
LU82102A1 (fr) | Matieres biocompatibles et compatibles avec le sang,ainsi que leurs procedes de fabrication | |
MXPA05006631A (es) | Metodo para hacer dispositivos que tienen cubiertas antimicrobianas sobre los mismos. | |
JP2005523116A (ja) | 生物学的に活性なポリマーケーシングを有する埋込み型医療装置 | |
KR20130045836A (ko) | 바이오필름 내성 물질 | |
Delaviz et al. | Infection resistant biomaterials | |
Dhiman et al. | Silver-based polymeric nanocomposites as antimicrobial coatings for biomedical applications | |
Sun et al. | Inspired by the periodontium: a universal bacteria-defensive hydrogel for preventing percutaneous device-related infection | |
EP0954341B1 (de) | Intraokulare linse mit abzugebendem medikament | |
EP3010942B1 (de) | Oberflächenmodifizierung von humanmedizinischen oder veterinärmedizinischen vorrichtungen | |
RU2462273C1 (ru) | Способ обработки синтетических текстильных имплантируемых медицинских изделий, контактирующих с кровью | |
FR2959938A1 (fr) | Sonde urinaire comportant des proanthocyanidines et son mode d'utilisation | |
Zhu et al. | Anti-biofouling and antimicrobial biomaterials for tissue engineering | |
Park et al. | Oleamide–PDMS copolymer for coating urinary catheters with anti-adhesive and anti-biofilm properties | |
Gottenbos | The development of antimicrobial biomaterial surfaces | |
Li et al. | Fighting against biofilm: The antifouling and antimicrobial material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100528 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20110411 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110503 |